Welcome to the international HTA database

Showing [20829 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cenegermin (moderate or severe neurotrophic keratitis) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cenobamate (epilepsy) - Addendum to Commission A21-78]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Central auditory processing disorder diagnosis]
2006	The Netherlands Organisation for Health Research and Development (ZonMw)	[Centralized Implementation of accurate and efficient preoperative staging using multislice CT, endoultrasonographic fine needle biopsy (EUS-FNA) and positron emission tomography (FDG-PET) in esophageal cancer patients: Cimple study]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib (lung cancer): Addendum to Commission A16-62]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib (lung cancer): benefit assessment according to §35a Social Code Book V; expiry of the decision
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ceritinib in lung cancer]
2022	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cerliponase alfa (neuronal ceroid lipofuscinosis type 2) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cerliponase alfa (neuronal ceroid lipofuscinosis) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cerliponase alfa in neuronal ceroid lipofuscinosis type 2]
2017	Agenzia nazionale per i servizi sanitari regionali (Agenas)	[Cervical and lumbar total disc replacement - HTA report adaptation]
2010	Haute Autorite de sante (HAS)	[Cervical length measurement with transvaginal ultrasonography to predict spontaneous preterm birth]
2011	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cessation of smoking in essential hypertension - Rapid report]
2006	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Cetuximah given in combination for patients with colorectal cancer]
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2018	Basque Office for Health Technology Assessment (OSTEBA)	[Checklist for ethical and legal domains analysis]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Chemoembolization and radioembolization for the treatment of liver metastases]
2002	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Chlamydia screening with home testing - a health technology assessment]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cholic acid - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2012	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]
2008	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cholinesterase inhibitors in Alzheimer's disease]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[ChondroCelect® in patients with knee cartilage injury]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Chromosomal microarrays for the etiologic diagnosis in patients with intellectual disability, developmental delay or autism spectrum]
2010	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Chronic fatigue syndrome: state of the evidence and assessment of intervention modalities in Quebec]
2002	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Chronic hepatitis C. Combination therapy IFN and ribavirin]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Chronic low back pain: the appropriate use of diagnostic imaging procedures]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Chronic periodontitis - prevention, diagnosis and treatment]
2014	The Swedish Council on Health Technology Assessment (SBU)	[Chronic ulcers in the elderly – prevention and treatment]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cidofovir for the treatment of recurrent respiratory papillomatosis]
2010	The Swedish Council on Health Technology Assessment (SBU)	[Cilostazol for treatment of intermittent claudication]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Circulating tumour cells in breast cancer: clinical use of the CellSearch® test]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Classification of disease severity for neuro- and trauma rehabilitation Part 3: Status quo in Austria]
2008	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Clavicular fractures - a systematic review about efficacy and safety of different treatment options]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2012	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Clinical effectiveness and cost-effectiveness of central venous catheters treated with minocycline and rifampicin in preventing bloodstream infections in intensive care patients]
2014	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Clinical effectiveness and cost-effectiveness of fissure sealants in children and adolescents with a high caries risk]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical effectiveness and cost-effectiveness of non-invasive telemonitoring on patients with heart failure]
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Clinical effectiveness and safety of robotic surgery]
2005	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Clinical effectiveness of carvedilol in comparison to -blockers, systematic review of the clinical and economic literature]
2005	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Clinical effectiveness of indapamide; systematic review of the clinical and economic literature]
2007	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry. Systematic Review]
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry: Maple Syrup Urine Disease, Homocystinuria, Glutaric Aciduria Type I, Isovaleric Acidaemia, Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency]
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: Beta-kethiolase deficiency (BKT); 3-Hydroxy-3-methyl glutaric aciduria (HMG)]
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: β-ketothiolase deficiency (BKT); 3-hydroxy-3-methyl glutaric aciduria (HMG)]
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism. Part II: Methylmalonic acidemia, Propionic acidemia, Tyrosinemia type I]
2018	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for severe combined immunodeficiency]
2009	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness of ozone therapies]
2009	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness of ozone therapies]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2022	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Clinical guides in antibiotic treatment – 1st series (update)]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Clinical guides in antibiotic treatment, 2nd series]
2007	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical impact of capsule endoscopy in obscure gastrointestinal bleeding. Systematic review]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical Practice Guideline about breastfeeding]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical practice guideline for attention deficit hyperactivity disorder (ADHD) in children and adolescents]
2001	Andalusian Health Technology Assessment Area (AETSA)	[Clinical practice guideline for medical management of otitis media in childhood]
2012	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical practice guideline of care for people with multiple sclerosis]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical practice guideline on acute bronchiolitis]
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Practice Guideline on adult's palliative care]
2010	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on assistance at normal childbirth]
2005	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on asthma]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical practice guideline on borderline personality disorders]
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical Practice Guideline on Childhood Asthma]
2014	Andalusian Health Technology Assessment Area (AETSA)	[Clinical practice guideline on intravenous therapy with temporary devices in adults]
2007	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on low back pain]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical practice guideline on osteoporosis and prevention of fragility fractures]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on palliative care]
2012	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Practice Guideline on prevention and management of suicidal behaviour]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical Practice Guideline on the care for people with alzheimer's disease and dementia]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Clinical practice guideline on the diagnostic, treatment and prevention of tuberculosis]
2007	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on the management of head injury in the field of extra and initial hospital care]
2017	Andalusian Health Technology Assessment Area (AETSA)	[Clinical practice guideline on the management of vasomotor and vaginal symptoms associated with menopause and postmenopause]
2012	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on type 1 diabetes]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guideline on type 2 diabetes]
2017	Andalusian Health Technology Assessment Area (AETSA)	[Clinical practice guidelines for hemotherapy. Brief report]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Clinical practice guidelines for the rehabilitation of adults having sustained a moderate to severe traumatic brain injury: development process and recommendations]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guidelines on arterial hypertension (2007 update)]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical practice guidelines on lipid management as a cardiovascular risk factor]
2018	Andalusian Health Technology Assessment Area (AETSA)	[Clinical practice guidelines on severe mental disorder]
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical Practice Guidelines on the diagnosis and treatment of non-serious blunt chest trauma]
2014	National Evidence-based Healthcare Collaborating Agency (NECA)	[Clinical safety and effectiveness of robotic surgery (2)]
2021	Andalusian Health Technology Assessment Area (AETSA)	[Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2013	Haute Autorite de sante (HAS)	[Clinical utility of the measurement of vitamin D]
2012	National Evidence-based Healthcare Collaborating Agency (NECA)	[Clinically relevant venous thromboembolism following hip and knee arthroplasty]
2009	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Clopidogrel plus acetylsalicylic acid in acute coronary syndrome]
2006	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Closed vs open systems for the preparation and administration of cytostatic and other hazardous drugs (NIOSH Group 1): analysis of the scientific evidence, costs and organisational requirements]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[CO2 Laser surgery in patients with otosclerosis]
2009	Committee for New Health Technology Assessment (CNHTA)	[CoaguChek XS PT TEST]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cobimetinib - Benefit assessment according to §35a Social Code Book V]